恒瑞医药(600276) - 2018 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2018 was approximately RMB 3.86 billion, representing a year-on-year increase of 21.70% compared to RMB 3.17 billion in the same period last year[7]. - The net profit attributable to shareholders of the listed company reached approximately RMB 949.45 million, an increase of 16.95% from RMB 811.85 million in the previous year[7]. - The basic earnings per share for the period were RMB 0.33, reflecting a 13.79% increase from RMB 0.29 in the same period last year[7]. - Operating profit for the quarter was ¥1,166,554,281.49, an increase of 23.1% from ¥948,389,555.65 in Q1 2017[23]. - Net profit for Q1 2018 was ¥897.54 million, up 16.1% from ¥772.94 million in Q1 2017[25]. - Operating profit increased to ¥1.06 billion, representing a growth of 15.9% compared to ¥914.17 million in the previous year[25]. Assets and Liabilities - The total assets at the end of the reporting period were approximately RMB 18.90 billion, an increase of 4.78% compared to RMB 18.04 billion at the end of the previous year[7]. - Total assets as of March 31, 2018, amounted to ¥18,902,238,600.32, compared to ¥18,039,384,776.48 at the beginning of the year, reflecting a growth of 4.8%[19]. - Total liabilities decreased to ¥1,907,223,105.92 from ¥2,096,169,951.25, a reduction of 9.0%[19]. - The company’s total equity increased to ¥16,995,015,494.40 from ¥15,943,214,825.23, reflecting a growth of 6.6%[19]. Cash Flow - The net cash flow from operating activities decreased by 18.71% to RMB 495.60 million, down from RMB 609.66 million in the same period last year[7]. - Cash flow from operating activities generated a net amount of ¥495.60 million, down 18.7% from ¥609.66 million in Q1 2017[27]. - The company reported cash inflow from investment activities of ¥3.31 billion, significantly higher than ¥619.51 million in the same quarter last year[27]. - Total cash and cash equivalents at the end of Q1 2018 amounted to ¥4.42 billion, a decrease from ¥5.96 billion at the end of Q1 2017[27]. - The company paid ¥1.61 billion in other operating cash payments, an increase of 19.3% from ¥1.35 billion in the previous year[30]. - The company’s investment activities resulted in a net cash outflow of ¥341.36 million, compared to a net inflow of ¥455.07 million in Q1 2017[27]. Investment and R&D - The company reported a significant increase in investment income, which rose by 1025.17% to RMB 55.74 million, compared to RMB 4.95 million in the previous year[15]. - The company plans to continue focusing on R&D for new products and technologies to enhance market competitiveness[30]. Shareholder Information - The total number of shareholders at the end of the reporting period was 70,591, indicating a stable shareholder base[11]. - The net assets attributable to shareholders of the listed company increased by 6.69% to approximately RMB 16.40 billion from RMB 15.37 billion at the end of the previous year[7].